Trial Profile
A PHASE IB, OPEN-LABEL, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF THE EBOLA CHIMPANZEE ADENOVIRUS VECTOR VACCINES, VRC-EBOADC069-00-VP (cAd3-EBO) AND VRC-EBOADC076-00-VP (cAd3-EBOZ), IN HEALTHY ADULTS IN KAMPALA, UGANDA
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2020
Price :
$35
*
At a glance
- Drugs GSK 3390107A (Primary) ; VRC-EBOADC069-00-VP (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 15 Jun 2020 Planned End Date changed from 1 Jun 2017 to 31 Mar 2016.
- 15 Jun 2020 Planned primary completion date changed from 1 Jan 2017 to NULL.
- 15 Jun 2020 Status changed from completed to recruiting.